Nuclear Factor kappa-light-chain-enhancer of activated B cells (NFκB) has been identified as a pivotal transcription factor in IBD pathogenesis (96) and polymorphisms in genes implicated in the NFκB-mediated primary response have been linked to anti-TNF treatment response in an IBD patient cohort study (97). Here, NFKB1 is linked to inflammatory bowel disease.